| UniProt ID | ASB2_HUMAN | |
|---|---|---|
| UniProt AC | Q96Q27 | |
| Protein Name | Ankyrin repeat and SOCS box protein 2 | |
| Gene Name | ASB2 | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 587 | |
| Subcellular Localization | ||
| Protein Description | Substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins.; Isoform 1: Enhances adhesion of hematopoietic cells to fibronectin through targeting of filamins FLNA and FLNB for proteasomal degradation, it is transiantly expressed during hematopoietic cell differentiation.; Isoform 2: Involved in myogenic differentiation and targets filamin FLNB for proteasomal degradation but not filamin FLNA.. | |
| Protein Sequence | MTRFSYAEYFSLFHSCSAPSRSTAPPESSPARAPMGLFQGVMQKYSSSLFKTSQLAPADPLIKAIKDGDEEALKTMIKEGKNLAEPNKEGWLPLHEAAYYGQVGCLKVLQRAYPGTIDQRTLQEETAVYLATCRGHLDCLLSLLQAGAEPDISNKSRETPLYKACERKNAEAVKILVQHNADTNHRCNRGWTALHESVSRNDLEVMQILVSGGAKVESKNAYGITPLFVAAQSGQLEALRFLAKYGADINTQASDNASALYEACKNEHEEVVEFLLSQGADANKTNKDGLLPLHIASKKGNYRIVQMLLPVTSRTRIRRSGVSPLHLAAERNHDEVLEALLSARFDVNTPLAPERARLYEDRRSSALYFAVVNNNVYATELLLQHGADPNRDVISPLLVAIRHGCLRTMQLLLDHGANIDAYIATHPTAFPATIMFAMKCLSLLKFLMDLGCDGEPCFSCLYGNGPHPPAPQPSSRFNDAPAADKEPSVVQFCEFVSAPEVSRWAGPIIDVLLDYVGNVQLCSRLKEHIDSFEDWAVIKEKAEPPRPLAHLCRLRVRKAIGKYRIKLLDTLPLPGRLIRYLKYENTQ | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
|
||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 28 | Phosphorylation | RSTAPPESSPARAPM CCCCCCCCCCCCCCC | 47.60 | - | |
| 29 | Phosphorylation | STAPPESSPARAPMG CCCCCCCCCCCCCCH | 22.40 | - | |
| 45 | Phosphorylation | FQGVMQKYSSSLFKT HHHHHHHHHHCHHCH | 9.26 | 29978859 | |
| 46 | Phosphorylation | QGVMQKYSSSLFKTS HHHHHHHHHCHHCHH | 22.08 | 29978859 | |
| 47 | Phosphorylation | GVMQKYSSSLFKTSQ HHHHHHHHCHHCHHC | 28.15 | 29978859 | |
| 48 | Phosphorylation | VMQKYSSSLFKTSQL HHHHHHHCHHCHHCC | 31.70 | 24719451 | |
| 51 | Ubiquitination | KYSSSLFKTSQLAPA HHHHCHHCHHCCCCC | 53.19 | - | |
| 52 | Phosphorylation | YSSSLFKTSQLAPAD HHHCHHCHHCCCCCC | 17.86 | 29978859 | |
| 53 | Phosphorylation | SSSLFKTSQLAPADP HHCHHCHHCCCCCCH | 24.64 | 29978859 | |
| 88 | Ubiquitination | KNLAEPNKEGWLPLH CCCCCCCCCCCEEHH | 69.21 | - | |
| 107 | Ubiquitination | YGQVGCLKVLQRAYP HHHHHHHHHHHHHCC | 45.00 | - | |
| 155 | Ubiquitination | AEPDISNKSRETPLY CCCCCCCCCCCCHHH | 44.06 | - | |
| 162 | Phosphorylation | KSRETPLYKACERKN CCCCCHHHHHHHHCC | 9.57 | - | |
| 168 | Acetylation | LYKACERKNAEAVKI HHHHHHHCCHHHHEE | 37.91 | 20167786 | |
| 199 | Phosphorylation | TALHESVSRNDLEVM HHHCHHCCCCCCCHH | 34.35 | 28509920 | |
| 219 | Ubiquitination | GGAKVESKNAYGITP CCCEEECCCCCCCCH | 31.90 | - | |
| 312 | Phosphorylation | VQMLLPVTSRTRIRR EEEEEECCCCCCHHH | 15.56 | 28509920 | |
| 313 | Phosphorylation | QMLLPVTSRTRIRRS EEEEECCCCCCHHHC | 31.71 | 28509920 | |
| 323 | Phosphorylation | RIRRSGVSPLHLAAE CHHHCCCCHHHHHHH | 25.85 | - | |
| 342 | Phosphorylation | EVLEALLSARFDVNT HHHHHHHHCCCCCCC | 20.46 | 24719451 | |
| 442 | Phosphorylation | MFAMKCLSLLKFLMD HHHHHHHHHHHHHHH | 40.92 | 24719451 | |
| 582 | Ubiquitination | GRLIRYLKYENTQ-- HHHHHHHEECCCC-- | 41.40 | - |
| Modified Location | Modified Residue | Modification | Function | Reference | ||
|---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of ASB2_HUMAN !! | ||||||
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of ASB2_HUMAN !! | ||||||
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| There are no disease associations of PTM sites. | ||||||
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| There are no disease associations of PTM sites. | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
loading...